Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + docetaxel + androgen deprivation therapy
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
This investigational combination therapy consists of the PD-1 inhibitor nivolumab, the taxane chemotherapy docetaxel, and androgen deprivation therapy (ADT). It is being evaluated in a Phase 2 clinical trial (NCT04126070) led by Dr. Xiao X. Wei for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The regimen aims to leverage the synergistic effects of hormonal suppression, cytotoxic chemotherapy, and immune checkpoint blockade. Patients are stratified based on DNA damage repair (DDR) defects and tumor inflammation status (PD-L1 and CD8+ T-cell infiltration). ADT in this regimen typically involves GnRH agonists like leuprolide or goserelin, or GnRH antagonists like degarelix, to suppress testosterone production and inhibit androgen receptor-driven tumor growth.
- Brand names
- OpdivoTaxotereLupronZoladexFirmagon
- Other names
- Nivolumab + Docetaxel + ADT
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on nivolumab + docetaxel + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + docetaxel + androgen deprivation therapy.